COGENT BIOSCIENCES INC (COGT)
US19240Q2012 - Common Stock
Cogent Biosciences Becomes Oversold (COGT)
Which stocks are moving after the closing bell on Tuesday?
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Why Is Cogent Biosciences Stock Trading Higher On Monday?
On Sunday, Cogent Biosciences, Inc. (NASDAQ:COGT) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. Non-advanced systemic mastocytosis is a rare disease that involves mast cell buildup in tissues and organs. Updated clinical data presented at the American Society of Hematology Annual Meeting & Exposition show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks. 76% of
Curious about the stocks that are showing activity before the opening bell on Monday?
Get insights into the top gainers and losers of Monday's pre-market session.
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg...
Cogent Biosciences Becomes Oversold (COGT)
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial initiated for CGT-4859, a reversible,...
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q2 2024
COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the second quarter of 2024.
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cogent Biosciences (NASDAQ:COGT) just reported results for the second quarter o...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q...
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line results expected by end of 2025...
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST...
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024
COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the first quarter of 2024.
Cogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q...
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
IND-enabling studies expected to begin mid-2024
Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options
Cogent downgraded at Baird on rare disease drug data (NASDAQ:COGT)
Baird downgrades Cogent Biosciences to neutral as disappointing data for bezuclastinib raises concerns. Read more here.
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
• UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg...
Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib (NASDAQ:COGT)
Cogent Biosciences (COGT) stock jumped 10% Thursday after the company reported positive data for its drug candidate bezuclastinib in the treatment of NonAdvSM. Read more here.
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based...
Bullish Two Hundred Day Moving Average Cross - COGT
Cogent Biosciences announces oversubscribed $225M private placement (NASDAQ:COGT)
Cogent Biosciences has entered into a private investment in public equity financing, raising $225 million to fund R&D activities and general corporate...
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK...
Citi starts Cogent Biosciences at buy, cites GI tumor drug potential (NASDAQ:COGT)
Citi has initiated coverage of Cogent Biosciences (COGT) with a buy rating, citing the potential of the company’s drug bezuclastinib in the treatment of systemi
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET...
Cogent Biosciences issues study updates on bezuclastinib, CGT4859 (NASDAQ:COGT)
Cogent Biosciences (COGT) issued a clinical testing update for its drug candidates bezuclastinib and CGT4859 ahead of a presentation at the annual JP Morgan Healthcare Conference.
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete...
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...